BRENDA - Reference to 3.4.22.26; Id = 30160

additional information

no activation with 0.005 mM cysteine and 4 mM KCN

Homo sapiens

additional information

no activation with 0.005 mM cysteine and 4 mM KCN

Rattus norvegicus

Polyethylene glycol preparation yields stable enzyme

Homo sapiens

Polyethylene glycol preparation yields stable enzyme

Rattus norvegicus

Prefers lipid environment, phospholipids stabilize

Homo sapiens

Prefers lipid environment, phospholipids stabilize

Rattus norvegicus

Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum

Homo sapiens

Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum

Rattus norvegicus

alpha1-Aantichymotrypsin

weak

Homo sapiens

alpha1-Aantichymotrypsin

weak

Rattus norvegicus

alpha2-Macroglobulin

weak

Homo sapiens

alpha2-Macroglobulin

weak

Rattus norvegicus

antipain

enhanced in reduced environment

Homo sapiens

antipain

enhanced in reduced environment

Rattus norvegicus

diisopropylfluorophosphate

strong

Homo sapiens

diisopropylfluorophosphate

strong

Rattus norvegicus

HgCl2

strong, less effective in reduced environment

Homo sapiens

HgCl2

strong, less effective in reduced environment

Rattus norvegicus

iodoacetamide

strong, still enhanced in reduced environment

Homo sapiens

iodoacetamide

strong, still enhanced in reduced environment

Rattus norvegicus

leupeptin

enhanced in reduced environment

Homo sapiens

leupeptin

enhanced in reduced environment

Rattus norvegicus

additional information

cystatin, alpha1-antiprotease, antithrombin III

Homo sapiens

additional information

cystatin, alpha1-antiprotease, antithrombin III

Rattus norvegicus

Peptidyl chloromethanes

-

Homo sapiens

Peptidyl chloromethanes

-

Rattus norvegicus

Peptidyl diazomethanes

-

Homo sapiens

Peptidyl diazomethanes

-

Rattus norvegicus

Peptidyl dimethylsulfonium salts

-

Homo sapiens

Peptidyl dimethylsulfonium salts

-

Rattus norvegicus

phenylmethylsulfonyl fluoride

-

Homo sapiens

phenylmethylsulfonyl fluoride

-

Rattus norvegicus

trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane

enhanced in reduced environment

Homo sapiens

trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane

enhanced in reduced environment

Rattus norvegicus

Ca2+

requirement, 7 mM

Homo sapiens

Ca2+

requirement, 7 mM

Rattus norvegicus

Mg2+

10 mM; requirement, can replace Ca2+

Homo sapiens

Mg2+

10 mM; requirement, can replace Ca2+

Rattus norvegicus

Mn2+

but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+

Homo sapiens

Mn2+

but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+

Rattus norvegicus

additional information

binding cancer procoagulant to a surface changes its divalent ion requirements

Homo sapiens

additional information

binding cancer procoagulant to a surface changes its divalent ion requirements

Rattus norvegicus

additional information

-

amino acid composition of rabbit V2 and human amnion-chorion enzymes

Homo sapiens

additional information

-

Rattus norvegicus

Homo sapiens

-

Rattus norvegicus

-

sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize

Homo sapiens

sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize

Rattus norvegicus

no glycoprotein

Homo sapiens

no glycoprotein

Rattus norvegicus

amelanotic melanoma cell

-

Rattus norvegicus

-

carcinoma cell

-

Rattus norvegicus

-

Lewis lung carcinoma cell

-

Rattus norvegicus

-

additional information

unique in fetal tissues, not in normally differentiated tissues; unique in tumor

Homo sapiens

-

additional information

unique in fetal tissues, not in normally differentiated tissues; unique in tumor

Rattus norvegicus

-

placenta

amnion-chorion tissue

Homo sapiens

-

Walker carcinoma 256 cell

-

Rattus norvegicus

-

Factor X + H2O

primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19

30160

Homo sapiens

Factor Xa + ?

-

30160

Homo sapiens

-

Factor X + H2O

primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19

30160

Rattus norvegicus

Factor Xa + ?

-

30160

Rattus norvegicus

-

37

-

assay at

Homo sapiens

37

-

assay at

Rattus norvegicus

additional information

no activation with 0.005 mM cysteine and 4 mM KCN

Homo sapiens

additional information

no activation with 0.005 mM cysteine and 4 mM KCN

Rattus norvegicus

Polyethylene glycol preparation yields stable enzyme

Homo sapiens

Polyethylene glycol preparation yields stable enzyme

Rattus norvegicus

Prefers lipid environment, phospholipids stabilize

Homo sapiens

Prefers lipid environment, phospholipids stabilize

Rattus norvegicus

Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum

Homo sapiens

Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum

Rattus norvegicus

alpha1-Aantichymotrypsin

weak

Homo sapiens

alpha1-Aantichymotrypsin

weak

Rattus norvegicus

alpha2-Macroglobulin

weak

Homo sapiens

alpha2-Macroglobulin

weak

Rattus norvegicus

antipain

enhanced in reduced environment

Homo sapiens

antipain

enhanced in reduced environment

Rattus norvegicus

diisopropylfluorophosphate

strong

Homo sapiens

diisopropylfluorophosphate

strong

Rattus norvegicus

HgCl2

strong, less effective in reduced environment

Homo sapiens

HgCl2

strong, less effective in reduced environment

Rattus norvegicus

iodoacetamide

strong, still enhanced in reduced environment

Homo sapiens

iodoacetamide

strong, still enhanced in reduced environment

Rattus norvegicus

leupeptin

enhanced in reduced environment

Homo sapiens

leupeptin

enhanced in reduced environment

Rattus norvegicus

additional information

cystatin, alpha1-antiprotease, antithrombin III

Homo sapiens

additional information

cystatin, alpha1-antiprotease, antithrombin III

Rattus norvegicus

Peptidyl chloromethanes

-

Homo sapiens

Peptidyl chloromethanes

-

Rattus norvegicus

Peptidyl diazomethanes

-

Homo sapiens

Peptidyl diazomethanes

-

Rattus norvegicus

Peptidyl dimethylsulfonium salts

-

Homo sapiens

Peptidyl dimethylsulfonium salts

-

Rattus norvegicus

phenylmethylsulfonyl fluoride

-

Homo sapiens

phenylmethylsulfonyl fluoride

-

Rattus norvegicus

trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane

enhanced in reduced environment

Homo sapiens

trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane

enhanced in reduced environment

Rattus norvegicus

Ca2+

requirement, 7 mM

Homo sapiens

Ca2+

requirement, 7 mM

Rattus norvegicus

Mg2+

10 mM; requirement, can replace Ca2+

Homo sapiens

Mg2+

10 mM; requirement, can replace Ca2+

Rattus norvegicus

Mn2+

but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+

Homo sapiens

Mn2+

but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+

Rattus norvegicus

additional information

binding cancer procoagulant to a surface changes its divalent ion requirements

Homo sapiens

additional information

binding cancer procoagulant to a surface changes its divalent ion requirements

Rattus norvegicus

additional information

-

amino acid composition of rabbit V2 and human amnion-chorion enzymes

Homo sapiens

additional information

-

Rattus norvegicus

sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize

Homo sapiens

sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize

Rattus norvegicus

no glycoprotein

Homo sapiens

no glycoprotein

Rattus norvegicus

amelanotic melanoma cell

-

Rattus norvegicus

-

carcinoma cell

-

Rattus norvegicus

-

Lewis lung carcinoma cell

-

Rattus norvegicus

-

additional information

unique in fetal tissues, not in normally differentiated tissues; unique in tumor

Homo sapiens

-

additional information

unique in fetal tissues, not in normally differentiated tissues; unique in tumor

Rattus norvegicus

-

placenta

amnion-chorion tissue

Homo sapiens

-

Walker carcinoma 256 cell

-

Rattus norvegicus

-

Factor X + H2O

primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19

30160

Homo sapiens

Factor Xa + ?

-

30160

Homo sapiens

-

Factor X + H2O

primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19

30160

Rattus norvegicus

Factor Xa + ?

-

30160

Rattus norvegicus

-

37

-

assay at

Homo sapiens

37

-

assay at

Rattus norvegicus

733446

Kee

The effect of cancer procoagul ...

Homo sapiens

Biol. Chem.

393

113-121

2012

-

3

-

1

-

1

-

1

-

701292

Musallam

Incidence and prophylaxis of v ...

Homo sapiens

Thromb. Res.

123

679-686

2009

-

1

-

2

-

1

-

1

-

1

-

710603

Kaplinska

Cancer procoagulant (CP) analy ...

Homo sapiens

Thromb. Res.

124

364-367

2009

-

2

-

1

2

-

2

-

2

-

1

-

2

-

1

2

-

2

-

1

-

697471

Kamocka

Rat prostate tumors express ca ...

Rattus norvegicus

Comp. Med.

58

282-286

2008

-

2

-

2

-

3

-

1

-

2

11

-

3

-

1

-

1

-

1

2

-

2

-

1

-

2

11

-

3

-

1

-

679297

Kamocka

Effect of immunisation with ca ...

Homo sapiens

Clin. Exp. Med.

6

119-123

2006

-

1

-

1

-

1

-

4

-

1

-

2

-

1

-

1

-

1

-

1

-

1

-

2

-

1

-

679638

Szajda

Analysis of the relationship b ...

Homo sapiens

Eur. J. Gynaecol. Oncol.

27

495-499

2006

1

-

1

-

2

-

3

-

1

-

1

-

1

-

3

-

1

-

668075

Kazmierczak

Cancer procoagulant in patient ...

Homo sapiens

Blood Coagul. Fibrinolysis

16

543-547

2005

-

1

-

2

-

2

-

4

1

-

2

-

1

-

2

-

4

1

-

2

-

668137

Kamocka

Effect of cancer procoagulant ...

Homo sapiens

Cancer Lett.

222

89-94

2005

-

1

-

2

-

1

-

1

-

3

-

3

-

1

-

1

-

1

-

2

-

1

-

3

-

3

-

1

-

1

-

668476

Jozwik

The activity of cancer procoag ...

Homo sapiens

Eur. J. Gynaecol. Oncol.

26

407-410

2005

-

1

-

2

-

2

-

7

1

-

4

-

1

-

2

-

7

1

-

4

-

667302

Raasi

Properties of proteins in canc ...

Homo sapiens

Arch. Biochem. Biophys.

428

131-135

2004

-

2

-

2

-

1

-

1

-

1

-

1

-

1

-

2

-

2

-

1

-

1

-

1

-

1

-

651435

Mielicki

Biochemistry of cancer procoag ...

Homo sapiens, Oryctolagus cuniculus

Haemostasis

31 Suppl 1

8-10

2001

8

-

24

-

1

2

1

4

-

2

-

2

1

-

6

-

13

1

-

1

-

8

-

24

1

-

1

2

1

4

-

2

1

-

6

-

13

1

-

1

-

653983

Mielicki

Cancer procoagulant activity s ...

Homo sapiens

Thromb. Res.

87

251-256

1997

-

1

-

2

5

-

1

-

1

-

1

-

3

2

-

18

-

5

1

-

1

-

2

-

5

-

1

-

1

-

3

2

-

18

-

5

1

-

30160

Gordon

Cancer procoagulant ...

Homo sapiens, Rattus norvegicus

Methods Enzymol.

244

568-583

1994

2

-

6

26

-

8

2

-

2

-

7

-

2

-

2

-

2

-

6

-

26

-

8

2

-

2

-

7

-

2

-

2

-

30161

Mielicki

Effect of divalent ions on the ...

Homo sapiens

Arch. Biochem. Biophys.

314

165-170

1994

-

3

-

1

4

-

1

-

1

-

1

-

1

-

3

-

1

4

-

1

-

1

-

1

-

30159

Moore

The purification and propertie ...

Mus musculus

Biochem. Biophys. Res. Commun.

184

819-824

1992

-

12

-

1

-

3

-

1

-

6

-

1

4

1

-

12

-

1

-

1

-

6

-

1

4

1

-

30158

Falanga

Inhibition of cancer procoagul ...

Oryctolagus cuniculus

Thromb. Res.

54

389-398

1989

-

2

-

1

-

3

-

2

-

3

-

30157

Falanga

Several murine metastasizing t ...

Mus musculus, Oryctolagus cuniculus

Int. J. Cancer

39

774-777

1987

-

4

-

4

-

8

-

6

-

4

-

8

-

6

-

30156

Falanga

Isolation and characterization ...

Oryctolagus cuniculus

Biochemistry

24

5558-5567

1985

-

2

-

2

1

-

2

-

1

-

3

-

2

1

-

1

-

2

-

2

1

-

1

-

3

-

2

1

-

1

-

Cancer procoagulant

Data extracted from this reference: